There was a pretty high severe systemic adverse rate in the high dose group (20%). Severe local response rate was 5% in the middle dose. [1]
I have no idea how this compares to other vaccines, and you can pessimistically extrapolate a bit from this tiny, healthy sample from the high dose (n=15 in middle dose group).
I'd imagine some % of people when this scales to millions will have a bad response, and the high dose group might provide some model of the worst cases.
I have no idea how this compares to other vaccines, and you can pessimistically extrapolate a bit from this tiny, healthy sample from the high dose (n=15 in middle dose group).
I'd imagine some % of people when this scales to millions will have a bad response, and the high dose group might provide some model of the worst cases.
[1] https://www.nejm.org/doi/full/10.1056/nejmoa2022483